ClearPoint Neuro heads into the post-earnings session carrying a 46% one-month price rally, a heavily rebuilt short position, and a fresh Q1 result that landed on both sides of the line — sales above consensus, losses wider than expected.
Short interest is the dominant tension right now. It has climbed to 17.4% of the free float — up 6.7% in a single week and 16.6% over the past month. That's a meaningful rebuild: in mid-April, short interest was running closer to 13-14% of float, before bears added aggressively as the stock rallied. At 76.2 on the ORTEX short score, CLPT ranks near the top 2nd percentile for short pressure versus the broader universe. Days to cover sat at 11.85 per the latest FINRA fortnightly data — a wide cushion for shorts but also a significant squeeze risk if a positive catalyst lands.
The lending market is moderately tight, not extreme. Availability is running at roughly 43% of short interest, meaning fewer than half a share is still available for every share already borrowed — comfortably below the 200% threshold that signals normal conditions. Cost to borrow is low at 0.80%, down about 15% from a month ago, so there's no sign of an acute financing squeeze from the borrow side. What that combination tells you is that short positioning is elevated and the lending pool is getting snug, but shorts are not yet paying a premium for the privilege.
Options traders are not particularly hedged. The put/call ratio is 0.34, just a fraction below its 20-day average of 0.35, with a z-score close to zero. The 52-week range on the PCR runs from 0.12 at the bullish extreme to 0.51 at the most defensive reading — current positioning is squarely in the middle. Call volume continues to dominate, consistent with a stock that has been trending higher. That's a notable contrast with the short-interest picture: options traders are leaning constructive while short sellers have rebuilt aggressively.
The Q1 print itself adds a fresh wrinkle. Revenue came in at $12.1 million, beating the $12 million estimate, and management reaffirmed full-year 2026 sales guidance of $52-56 million. The EPS loss, however, widened to $(0.32) against a $(0.26) estimate — a meaningful gap that bears will point to as evidence that the growth story remains cash-consumptive. The company also announced CE marking in Europe for its Velocity Alpha MR High Speed Surgical Drill, on top of existing FDA 510(k) clearance, which broadens its addressable market into biologics-guided neurosurgery. The earnings history shows the stock gained 5.4% the day after the May 8 event and fell 12.9% after the March report — reactions that underscore how binary these prints have been.
Street coverage is thin but uniformly bullish. The most recent target came from B. Riley Securities in March, which raised to $20 after first cutting deeply from $28 — reflecting a reset followed by early recovery confidence. The consensus mean target is $22 against a current price of $12.64, implying roughly 74% upside to the Street's central case. The bull argument centres on biologics partnership growth and the trajectory toward reduced cash burn. The bear counter is that operating losses remain sizeable and competitive pressures could complicate scaling. MAK Capital One entered as a fresh institutional holder with a 5.8% stake as of March 13, and both BlackRock and Vanguard added shares in their most recent filings — adding credible buy-side support at lower price levels.
The next confirmed event is on May 20. With the Q1 result digested, the debate now shifts to whether the revenue reaffirmation is enough to sustain a stock that has already re-rated 46% higher in a month, against a short base that has been rebuilding all the way up.
See the live data behind this article on ORTEX.
Open CLPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
